https://semaglutideglpone.com/ Editorial news on semaglutide, telehealth providers, FDA actions, state pharmacy board decisions, clinical trial readouts, and pricing changes. en-us Wed, 20 May 2026 19:42:40 GMT semaglutideglpone@gmail.com (Joseph Safer, M.D.) https://semaglutideglpone.com/news.html#may-14-2026 semaglutideglpone-news-2026-05-14 Thu, 14 May 2026 00:00:00 GMT Eli Lilly's phase 3 cardiovascular safety analysis for orforglipron completes; Foundayo on track for Q4 2026 commercial launch. Full analysis: https://semaglutideglpone.com/clinical/foundayo-orforglipron.html https://semaglutideglpone.com/news.html#may-8-2026 semaglutideglpone-news-2026-05-08 Thu, 08 May 2026 00:00:00 GMT Florida, Texas, and California state pharmacy boards open formal investigations into 503A vs 503B classification at high-volume telehealth-supplied pharmacies. https://semaglutideglpone.com/news.html#may-5-2026 semaglutideglpone-news-2026-05-05 Tue, 05 May 2026 00:00:00 GMT ESSENCE phase 3 interim shows semaglutide 2.4 mg achieved approximately 62% MASH resolution at 72 weeks. Plausible 2027 FDA MASH indication. Full analysis: https://semaglutideglpone.com/clinical/semaglutide-and-mash.html https://semaglutideglpone.com/news.html#april-28-2026 semaglutideglpone-news-2026-04-28 Mon, 28 Apr 2026 00:00:00 GMT CMS expands Part D Wegovy coverage for adults with BMI ≥27 + established cardiovascular disease. First material Part D coverage expansion for a weight-management GLP-1 since 2003. https://semaglutideglpone.com/news.html#april-14-2026 semaglutideglpone-news-2026-04-14 Tue, 14 Apr 2026 00:00:00 GMT FDA action restricting ingredients in mass-marketed compounded GLP-1 medications. Salt forms (semaglutide sodium, acetate) flagged as unapproved API. Detailed: https://semaglutideglpone.com/clinical/april-2026-fda-action.html